 - Prioritizing next generation, more potent core inhibitors, triple combinations with complementary mechanisms of action, and expanding research programs to advance multiple candidates against novel targets - Extends cash runway into 2023 - Company to host conference call today at 5:00 p.m. ET2:00 p.m. PT 